1: Eisenberg, DM, David, RB, Ettner, SL, et al. Trends in alternative medicine use in the United States, 1990–1997. JAMA 1998; 280: 1569–75.
2: Heptinstall, S, White, A, Williamson, L, Mitchel, . Extracts of feverfew inhibit granule secretion in blood platelets and polymorphonuclear leucocytes. Lancet 1998; i: 1071–4.
3: De Weerdt, CJ, Bootsma, HPR, Hendriks, . Herbal medicines in migraine prevention: randomized double-blind placebo-controlled crossover trial of a feverfew preparation. Phytomedicine 1998; 3: 225–30.
4: Jadad, AR, Moore, RA, Carrol, D, Jenkinson, C, Reynolds, DJM, Gavaghan, , et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clin. Trials 1996; 17: 1–12.
5: Johnson, ES, Kadam, NP, Hylands, DM, Hylands, PJ. Efficacy of feverfew as prophylactic treatment of migraine. BMJ 1998; 291: 569–73.
6: Murphy, JJ, Heptinstall, S, Mitchell, JRA. Randomized double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet 1998; i: 189–92.
7: Palevitch, D, Earon, G, Carasso, . Feverfew (Tanacetum parthenium) as a prophylactic treatment for migraine: A double-blind placebo-controlled study. Phytother. Res. 1998; 11: 508–11.
8: Kuritzky, A, Elhacham, Y, Yerushalmi, Z, Hering, . Feverfew in the treatment of migraine: its effect on serotonin uptake and platelet activity. Neurology 1998; 44(Suppl. 2): 293P.
9: Pfaffenrath, V, Fischer, M, Friede, M, Heinneicke, V, Zepelin, HH. Clinical dose–response study for the investigation of efficacy and tolerability of. Tanacetum parthenium in migraine prophylaxis. Proceedings of Deutscher Schmerzkongress 1998.
10: Fetow, CW, Avila, JR. Complementary and Alternative Medicines. Springhouse: Philadelphia, 1999.
11: Boon, H, Smith, M. The Botanical Pharmacy. Kingston, Canada: Quarry Press, 1999.
12: Ernst, E.Possible interactions between synthetic and herbal medicinal products. Part 1: a systematic review of the indirect evidence. Perfusion 2000; 13: 4–15.
13: Lininger, SW. A–Z Guide to Drug–Herb–Vitamin Interactions. Rocklin, CA: Prima Publishing, 1999.
14: Newall, CA, Anderson, LA, Phillipson, JD. Herbal Medicines. London: The Pharmaceutical Press, 1996.
15: Brinker, R. Herb Contraindications and Drug Interactions. Sandy, OR: Eclectic Medical Publications, 1998.
16: Tfelt-Hansen, P, Nielsen, SL. Patient numbers needed in prophylactic migraine trials. Neuroepidemiology 1997; 6: 214–19.
17: Heptinstall, S, Groenewegen, WA, Spangenberg, P, Loesche, W.Extracts of feverfew may inhibit platelet behaviour via neutralization of sulphydryl groups. J. Pharm. Pharmacol. 1987; 39: 459–65.
18: Pugh, WJ, Sambo, K.Prostaglandin synthetase inhibitors in feverfew. J. Pharm. Pharmacol. 1988; 40: 743–5.
19: Makheja, AN, Bailey, JM. A platelet phospholipase inhibitor from the medicinal herb feverfew (Tanacetum parthenium). Prostaglandins Leukotrienes Med. 1982; 8: 653–60.
20: Awang, DVC. Prescribing therapeutic feverfew (Tanacetum parthenium (L.) Schultz Bip., syn. Chrysanthemum parthenium (L.) Bernh.). Integrative Med. 1998; 1: 11–13.
21: Goadsby, PJ. How do the currently used prophylactic agents work in migraine?. Cephalalgia 1997; 17: 85–92.
22: Brown, AMG, Edwards, CM, Davey, MR, Power, B, Lowe, KC. Pharmacological activity of feverfew (Tanacetum parthenium (L.) Schultz-Bip.): Assessment by inhibition of human polymorphonuclear leucocyte chemiluminescence in-vitro. J. Pharm. Pharmacol. 1998; 49: 558–61.
23: Hendriks, H, Bos, R, Woerdenbag, HJ. The essential oil of Tanacetum parthenium (L.) Schultz-Bip. Flavour Fragrance J. 1996; 11: 367–71.
24: Murch, SJ, Simmons, CB, Saxena, PK. Melatonin in feverfew and other medicinal plants. Lancet 1997; 350: 1598–9.
25: Brun, J, Claustrat, B, Saddier, P, Chazor, G.Nocturnal melatonin excretion is decreased in patients with migraine without aura attacks associated with menses. Cephalalgia 1995; 15: 136–9.
26: Willigmann, J, Freudenstein, J. Production of a stable feverfew (Tanacetum parthenium) extract as an active substance for a pharmaceutical product. Scharper Brümmer 1999 (internal document).
27: Anderson, D, Jenkinson, PC, Dewdney, RS, Blowers, SD, Johnson, ES, Kadam, NP. Chromosomal aberrations and sister chromatid exchanges in lymphocytes and urine mutagenicity of migraine patients: a comparison of chronic feverfew users and matched non-users. Hum. Toxicol. 1988; 7: 145–52.
28: Burry, JN. Compositae dermatitis in South Australia: Contact dermatitis from Chrysanthemum parthenium. Contact Dermatitis 1980; 6: 445.
29: Hausen, BM, Osmundsen, PE. Contact allergy to parthenolide in Tanacetum parthenium (L.) Schulz-Bip. (Feverfew, Asteraceae) and cross-reactions to related sesquiterpene lactone containing compositae species. Acta Derm. Venereol. 1983; 63: 308–14.
30: Johnson, ES. Patients who chew chrysanthemum leaves. MIMS Mag. 1983; 15 05: 32–5.
31: Easterbrook, PJ, Berlin, JA, Gopalan, R, Matthews, DR. Publication bias in clinical research. Lancet 1991; 337: 867–72.
32: Ernst, E, Pittler, MH. Alternative therapy bias [letter]. Nature 1997; 385: 480.
33: Pittler, MH, Abbot, NC, Harkness, EF, Ernst, E.Location bias in controlled clinical trials of complementary medicine. J. Clin. Epidemiol. 2000; 53: 485–9.
34: Ernst, E, ed. Herbal Medicine. A Concise Overview for Professionals. Oxford: Butterworth-Heinemann, 2000.